



STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL DRUGS: TOWARDS AN IMPLEMENTATION OF THE TREATMENT PATHWAY IN ONCO-HEMATOLOGY

WITH THE SUPPORT OF



SIE
"Società Italiana di Ematologia"



RAVENNA SALA CORELLI

26 - 27 MAY 2017

SCIENTIFIC CHAIR
LANZA FRANCESCO

26th May

1st Session: to transplant or not to Transplant:
This is the question

- 1st part 13.30 - 16.10
- 1) Hematopoietic Stem cell transplantation (HSCT) in the era of novel drugs: The EBMT perspective
 - 2) HSCT in acute myeloid leukemia
 - 3) HSCT in Philadelphia+ ALL
 - 4) Novel antibodies for Ph-neg ALL: can we use them as a bridge to transplant
 - 5) Infection Control Strategy In High Risk HSCT
 - 6) Treatment strategies for fungal infections

Amadori D, Gratwohl A, Lanza F

Duarte R, Spain
Nagler A, Istrael
Rambaldi A, Italy

Martinelli G, Italy
Aversa F, Italy
Luppi M, Italy

16.10 - 16.30 Coffee break

- 2nd part 16.30 - 19.00
- 1) Debate: Mobilization of HSCT in multiple myeloma: is chemotherapy still needed

Bonifazi F, Pedrazzoli P, Tosi P

No
Yes

Duarte R, Spain
Lanza F, Italy
Comoli P, Italy
Necchi A, Italy
Vliek S, Netherlands

Olivieri A, Italy

McGrath E, UK
Babic A, Switzerland

- 2) Cell therapy for solid tumors
- 3) HSCT for refractory-relapsed Germ cell tumor
- 4) HSCT in Breast cancer
- 5) Endothelial complications post SCT: how can we predict and prevent it? How can we treat it?
- 6) Quality management and accreditation in transplantation: is it worth doing!
- 7) Nurses impact on HSCT outcome

27th May

2nd Session: Novel drugs: too many or still not enough!
Is transplantation still the thing to do?

- 1st part 8.30 - 10.40
- 1) Novel drugs in low grade nHL: are them better than SCT
 - 2) How I treat aggressive CLL
 - 3) Which is the role of Immune check point inhibitors in malignant lymphomas
 - 4) Role of monoclonal antibodies for the management of Hodgkin's lymphoma patients who are candidate to HSCT
 - 5) Cellular therapy activity in Europe
 - 6) Immune check point inhibitors in solid tumors with special emphasis on lung cancer: can we use it in combination with cellular therapy?

Bay J, Pane F

Zaja F, Italy
Cuneo A, Italy

Carlostella C, Italy

Martino M, Italy
Bonini C, Italy

Bennati C, Italy

10.40 - 11.00 Coffee break

- 2nd part 11.00 - 13.30
- 1) Novel Monoclonal antibodies in MM
 - 2) Rethinking the treatment algorithm for Myelofibrosis:

BMT Yes
BMT No

Bacigalupo A, Lucchesi A
Malavasi F, Italy

Bacigalupo A, Italy
Barosi G, Italy
Hill A, UK
Dufour C, Italy

- 3) How I treat PNH
- 4) Transplantation in Aplastic anemia
- 5) Treatment of acute GVHD: Photoheresis in first or second line?
- 6) HSCT in the outpatient setting: how can we manage it!

Bacigalupo A, Italy
Martino M, Italy

ID ECM 2007 - 185655

Ecm Credits 6,3 (Formative credits used by Italian Ministry of Health) the following professional categories may participate in the meeting

Surgeon

specialist in Hematology, Medical Genetics, Internal Medicine, Oncology, Radiotherapy, Pathological Anatomy, Medical Genetics Lab, Trasfusion Medicine, General Medicine

Biologist

Biomedical Laboratory Technicians

Nurse

Event Organiser



Registration: www.proeventi.it

Unrestricted Educational Grant

